Sono stati resi noti i Late-Breaking Clinical Trials che verranno presentati nel corso delle Hot Line Sessions di ESC 2022, il prossimo Congresso dell’European Society of Cardiology in programma dal 26 al 29 agosto 2022 a Barcellona. Come sempre la redazione di Cardioinfo sarà presente al Congresso per interviste, news e approfondimenti.

“Abbiamo creato un programma Hot Lines davvero eccezionale per il Congresso ESC 2022 – ha commentato Stephen Windecker, chairman nel comitato scientifico dell’evento – e incoraggio tutti a esplorarli. I risultati di questi importanti studi clinici hanno il potenziale per migliorare gli outcome dei pazienti, avere un impatto sulla pratica clinica e informare le future linee guida”. Di seguito la lista degli studi, divisi per giornata congressuale:

Venerdì 26 agosto:

HOT LINE SESSION 1:

• TIME – The Treatment in Morning versus Evening study.
• A polypill strategy in secondary prevention: results of the SECURE trial
• PERSPECTIVE – Sacubitril/valsartan and cognitive function in HFmrEF and HFpEF

Sabato 27 agosto:

HOT LINE SESSION 2:

• DANCAVAS – Screening and intervention to prevent cardiovascular disease.
• ADVOR – Acetazolamide in acute heart failure.
• DANFLU-1 – High-dose vs. standard-dose quadrivalent influenza vaccine in elderly adults.
• BOX – Oxygen therapy in comatose OHCA patients.
• BOX – Optimizin blood pressure in post-resuscitation care.

HOT LINE SESSION 3:

• REVIVED – Percutaneous Revascularisation for Ischaemic Ventricular Dysfunction.
• ALL-HEART – Allopurinol and cardiovascular outcomes in ischaemic heart disease.
• EchoNet-RCT – Safety and Efficacy Study of AI LVEF.

HOT LINE SESSION 4:

• DELIVER – Dapagliflozin in Heart Failure with Mildly Reduced and Preserved Ejection Fraction.
• Pooled analysis of DAPA-HF and DELIVER.
• A Pre-Specified Meta-Analysis of DELIVER and EMPEROR-Preserved.

Domenica 28 agosto:

HOT LINE SESSION 5:

• INVICTUS – Rivaroxaban versus VKA for rheumatic atrial fibrillation.
• PACIFIC-AMI – Efficacy and safety of factor XIa inhibitor asundexian on top of dual antiplatelet therapy after acute myocardial infarction.
• PACIFIC-STROKE – Phase 2 Program of AntiCoagulation via Inhibition of FXIa by the oral Compound BAY 2433334 – non-cardioembolic STROKE study.
• AXIOMATIC-SSP: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.

HOT LINE SESSION 6:

• eBRAVE-AF – Smartphone-based AF screening.
• Causal AI substantially improves the validity of estimating cardiovascular risk and benefit.
• AI-ENHANCED detection of Aortic Stenosis.

HOT LINE SESSION 7:

• DanNICAD-2 – Perfusion scanning with MR or PET after a positive CT coronary angiography.
• The PRE18FFIR trial: Coronary Plaque Activity to Predict Recurrent Events.
• The FRAME-AMI trial.

Lunedì 29 agosto:

HOT LINE SESSION 8:

• ISCHEMIA-CKD EXTEND – Clinical Outcomes at 5 years of Follow-up.
• 15-month results of the MASTER DAPT trial.
• FOURIER-OLE: Primary Results.
• FIDELITY: Causes of mortality.
• PARADISE-MI trial – Win Ratio Analysis.

HOT LINE SESSION 9:

• CTT meta-analysis of the effects of statins on muscle symptoms.
• MTT – Assessing the effects of ARBs and beta-blockers in Marfan Syndrome.
• PANTHER – P2Y12 inhibitor versus aspirin monotherapy in patients with coronary artery disease.
• RTC – Radial versus femoral access for coronary procedures.

HOT LINE SESSION 10:

• COVID-PACT – Antithrombotic therapy in critically Ill COVID-19 patients.
• ACT Outpatient trial.
• ACT Inpatient trial.